Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.12) by 272.73 percent. This is a 12.77 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $10.084 million which missed the analyst consensus estimate of $10.250 million by 1.62 percent. This is a 17.42 percent increase over sales of $8.588 million the same period last year.